Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

2013 – Risk for bladder cancer associated with Actos ranges from 21% to 251% increase

Posted in Actos & Bladder Cancer

In 2013, a team of researchers led by RM Turner published a report in British Journal of Clinical Pharmacology that evaluated the connection between the thiazolidinedione class of drugs and the onset of bladder cancer.  Drugs in that class include diabetes drugs Avandia and Actos.

Evaluating 18 previously-conducted studies (13 observational studies and 5 randomized controlled trials), researchers write that “Meta-analysis showed a significantly higher overall risk of bladder cancer with pioglitazone in [randomized controlled trials] (7,878 participants; OR 2.51, 95% CI 1.09-5.80) and observational studies (>2.6 million patients; OR for ever-users vs. non-users 1.21 (95%CI 1.09-1.35).”  This means that the risk for bladder cancer among Actos (pioglitazone) users is between 21% and 251% higher than the risk faced by non-users.

Further, the study found that those who had consumed more than 28 grams of Actos total in the course of their diabetes treatment were 64% more likely to develop bladder cancer. This study did not find an association between bladder cancer and Avandia, though others have.

Sadly, the manufacturer of Actos failed time and again to notify users of the risk for bladder cancer, and accordingly, a number of Actos lawsuits have been filed.  If you or a loved one used Actos and suffered bladder cancer, you too may be entitled to significant financial compensation for your undue injury.  For a free, no-obligation case consultation, contact our team of Actos lawyers at the information provided below.  We have the compassion, experience, and resources required to win the justice you deserve.

(855) 452 – 5529

justinian@dangerousdrugs.us